People: SkyePharma PLC (SKP.L)

SKP.L on London Stock Exchange

257.50GBp
5:35am EDT
Price Change (% chg)

-0.50p (-0.19%)
Prev Close
258.00p
Open
258.00p
Day's High
259.00p
Day's Low
257.00p
Volume
13,049
Avg. Vol
489,063
52-wk High
266.00p
52-wk Low
53.93p

Search Stocks

Summary

Name Age Since Current Position

Frank Condella

59 2010 Non-Executive Independent Chairman of the Board

Peter Grant

58 2012 Chief Executive Officer, Executive Director

Andrew Derodra

47 2013 Chief Financial Officer, Executive Director

John Murphy

60 2006 General Counsel, Company Secretary

John Biles

66 2014 Non-Executive Director

Jean-Charles Tschudin

71 2014 Senior Non-Executive Independent Director

Thomas Werner

57 2009 Non-Executive Independent Director

Biographies

Name Description

Frank Condella

Mr. Frank C. Condella, Jr., is Non-Executive Independent Chairman of the Board of SkyePharma Plc. Frank became Non-Executive Chairman on 1 January 2010, having originally joined the Company as Chief Executive Officer in March 2006. He was first appointed to the Board in April 2006, stepping down as Chief Executive Officer on 1 September 2008, remaining on the Board as an Executive Director until 1 November 2008 when he became a Non-Executive Director. Frank is President, Chief Executive Officer and a Director of Columbia Laboratories, Inc and a Non-Executive Director of Prosonix Ltd. Previously, he was President of European Operations at IVAX, Chief Executive Officer of Faulding Pharmaceuticals, Vice-President of the Specialty Care Products business at Roche and Vice- President and General Manager of the Lederle unit of American Home Products. He is a US citizen and holds a BS in Pharmacy and an MBA from Northeastern University.

Peter Grant

Mr. Peter Grant is Chief Executive Officer, Executive Director of Skyepharma PLC. He was appointed Chief Executive Officer on 31 January 2012. He joined the Company and was appointed to the Board as Chief Financial Officer in November 2006 and, on taking the Chief Executive role, retained responsibility for the Group’s financial matters up to 25 November 2013. Previously, Peter Grant was Interim Chief Executive Officer of Voice Commerce Group, Group Finance Director at Eurodis Electron PLC, Chief Financial Officer at WorldPay plc and Group Finance Director, then Group Chief Executive at Molins PLC. Prior to this he held a variety of senior commercial, financial and general management roles in the General Electric Company plc group of companies. He holds an MA in Mathematics from Oxford University and is a Chartered Accountant.

Andrew Derodra

Mr. Andrew Derodra is Chief Financial Officer, Executive Director of Skyepharma PLC. Andrew has spent 25 years working in senior finance and strategic roles within five FTSE100 groups, most recently with Tate & Lyle PLC where he was Group Vice President Finance & Control from 2011. Prior to that he was with SABMiller Plc, where he held a succession of roles culminating in Business Transformation Director – Europe, before which he was with Diageo plc, British Airways Plc and Reed Elsevier PLC. He has a pending application for Fellowship of the Chartered Institute of Management Accountants and holds a BA (Hons) in Mathematics from Oxford University.

John Murphy

Mr. John Murphy is General Counsel, Company Secretary of Skyepharma PLC. He joined the Company as General Counsel in March 2006 and was appointed as Company Secretary in September 2006. John Murphy is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is Chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in Aeronautical Engineering from Bristol University and is a qualified solicitor.

John Biles

Mr. John A. Biles has been appointed as Non-Executive Director of the Company effective March 5, 2014. He is Chairman of the Audit Committees of Bodycote PLC, HellermannTyton Group PLC and Sutton and East Surrey Water PLC and is also Senior Independent Director of Bodycote and Sutton and East Surrey Water. Since 2001 he has served in numerous Non-Executive roles with major companies such as Amey PLC, Charter International PLC, Viridian Group PLC and Hermes Fund Management Limited, in each case also holding the position of Chairman of the Audit Committee. He qualified as a Chartered Accountant with Price Waterhouse & Co, following which he held the position of Financial Director at various subsidiaries of Racal Electronics Plc and then successively Group Finance Director of Chubb Security Plc and FKI Plc. He holds a Bachelor of Sciences Combined Honours degree in Chemistry and Physics from the University of Exeter.

Jean-Charles Tschudin

Mr. Jean-Charles Tschudin is Senior Non-Executive Independent Director of Skyepharma Plc. He was appointed to the Board as a Non-Executive Director in July 2007 and appointed as Senior Independent Director on 5 March 2014. He is Chairman of the Nomination & Governance Committee and a member of the Audit and Remuneration Committees. Jean-Charles Tschudin has 45 years’ experience in the pharma industry in the U.S., Europe and Latin America. He is the Senior Non-Executive Director of Sinclair IS Pharma plc. Previously, he was President and Chief Operating Officer for Yamanouchi Europe (now Astellas Europe), President of Europe at Cardinal Health, Vice President International at Johnson & Johnson and General Manager/Area Manager in several European countries and Latin America at Schering-Plough. He is a Swiss citizen, holds an Economics Business Degree from Georgetown University and is a Chartered Director.

Thomas Werner

Dr. Thomas Werner is Non-Executive Independent Director of SkyePharma PLC. He was appointed to the Board as a Non-Executive Director in May 2009. He is Chairman of the Remuneration Committee and is a member of the Audit and Nomination & Governance Committees. Thomas Werner has 30 years of experience in the pharmaceutical industry, previously as Senior Vice-President of GlaxoSmithKline where he was Managing Director for Germany and also coordinated their European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. Dr Werner is Chairman of 4SC AG and sits on the Boards of Basilea Pharmaceutica Ltd, SuppreMol GmbH, BSN Medical and Blackfield AG. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch foundation and was a Director of the American Chamber of Commerce in Germany representing healthcare companies. He is a German citizen and holds a degree in Chemistry from the University of Göttingen.

Basic Compensation

Name Fiscal Year Total

Frank Condella

86,000

Peter Grant

642,000

Andrew Derodra

79,000

John Murphy

--

John Biles

--

Jean-Charles Tschudin

--

Thomas Werner

--
As Of 30 Dec 2013

Options Compensation

Search Stocks